References analysis of the Wikipedia article "Inosine pranobex" in the English version

cancer.org (Global: 3,680^th place; English: 2,918^th place)

"Inosine Pranobex". American Cancer Society. Archived from the original on 23 August 2010. Retrieved 31 July 2013.

doi.org (Global: 2^nd place; English: 2^nd place)

Sliva J, Pantzartzi CN, Votava M (August 2019). "Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases". Advances in Therapy. 36 (8): 1878–1905. doi:10.1007/s12325-019-00995-6. PMC 6822865. PMID 31168764.

Petrova M, Jelev D, Ivanova A, Krastev Z (April 2010). "Isoprinosine affects serum cytokine levels in healthy adults". Journal of Interferon & Cytokine Research. 30 (4): 223–228. doi:10.1089/jir.2009.0057. PMID 20038210.

You Y, Wang L, Li Y, Wang Q, Cao S, Tu Y, et al. (June 2015). "Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients". The Journal of Dermatology. 42 (6): 596–601. doi:10.1111/1346-8138.12845. PMID 25819042.

Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. (October 2010). "Biology of interleukin-10" (PDF). Cytokine & Growth Factor Reviews. 21 (5): 331–344. doi:10.1016/j.cytogfr.2010.09.002. PMID 21115385.

Rumel Ahmed S, Newman AS, O'Daly J, Duffy S, Grafton G, Brady CA, et al. (January 2017). "Inosine Acedoben Dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: A clinical trial supporting anti-viral indications". International Immunopharmacology. 42: 108–114. doi:10.1016/j.intimp.2016.11.023. PMID 27912146.

Hersey P, Edwards A (January 1984). "Effect of isoprinosine on natural killer cell activity of blood mononuclear cells in vitro and in vivo". International Journal of Immunopharmacology. 6 (4): 315–320. doi:10.1016/0192-0561(84)90048-1. PMID 6207121.

Tsang KY, Pan JF, Swanger DL, Fudenberg HH (January 1985). "In vitro restoration of immune responses in aging humans by isoprinosine". International Journal of Immunopharmacology. 7 (2): 199–206. doi:10.1016/0192-0561(85)90027-X. PMID 2409037.

Tsang KY, Fudenberg HH, Pan JF, Gnagy MJ, Bristow CB (January 1983). "An in vitro study on the effects of isoprinosine on immune responses in cancer patients". International Journal of Immunopharmacology. 5 (6): 481–490. doi:10.1016/0192-0561(83)90041-3. PMID 6198297.

Ohnishi H, Kosuzume H, Inaba H, Okura M, Morita Y, Mochizuki H, et al. (October 1982). "Mechanism of host defense suppression induced by viral infection: mode of action of inosiplex as an antiviral agent". Infection and Immunity. 38 (1): 243–250. doi:10.1128/iai.38.1.243-250.1982. PMC 347725. PMID 6183209.

Gordon P, Brown ER (September 1972). "The antiviral activity of isoprinosine". Canadian Journal of Microbiology. 18 (9): 1463–1470. doi:10.1139/m72-224. PMID 4341918.

DeSimone C, Hadden JW (1987). "Prohost Modulation of Immunity by Isoprinosine and NPT 15392". Antibiosis and Host Immunity. Boston, MA: Springer US. pp. 279–290. doi:10.1007/978-1-4613-1901-6_32. ISBN 978-1-4612-9058-2.

Licht K, Hartl M, Amman F, Anrather D, Janisiw MP, Jantsch MF (January 2019). "Inosine induces context-dependent recoding and translational stalling". Nucleic Acids Research. 47 (1): 3–14. doi:10.1093/nar/gky1163. PMC 6326813. PMID 30462291.

Alseth I, Dalhus B, Bjørås M (June 2014). "Inosine in DNA and RNA". Current Opinion in Genetics & Development. 26: 116–123. doi:10.1016/j.gde.2014.07.008. PMID 25173738.

Muldoon RL, Mezny L, Jackson GG (September 1972). "Effect of isoprinosine against influenza and some other viruses causing respiratory diseases". Antimicrobial Agents and Chemotherapy. 2 (3): 224–228. doi:10.1128/AAC.2.3.224. PMC 444295. PMID 4790561.

Waldman RH, Ganguly R (March 1977). "Therapeutic efficacy of inosiplex (Isoprinosine) in rhinovirus infection". Annals of the New York Academy of Sciences. 284 (1): 153–160. Bibcode:1977NYASA.284..153W. doi:10.1111/j.1749-6632.1977.tb21946.x. PMID 81636.

Melekhina E, Muzyka A, Lysenkova M, Gorelov A (2018). "A comparative analysis of therapeutic regimens in children with monthly respiratory infections and reactivation of infection caused by human herpesvirus type 6". Voprosy praktičeskoj pediatrii. 13 (5): 74–82. doi:10.20953/1817-7646-2018-5-74-82. ISSN 1817-7646.

Hashimoto K, Hosoya M (January 2021). "Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis". Molecules. 26 (2): 427. doi:10.3390/molecules26020427. PMC 7830519. PMID 33467470.

Davidson-Parker J, Dinsmore W, Khan MH, Hicks DA, Morris CA, Morris DF (December 1988). "Immunotherapy of genital warts with inosine pranobex and conventional treatment: double blind placebo controlled study". Genitourinary Medicine. 64 (6): 383–386. doi:10.1136/sti.64.6.383. PMC 1194272. PMID 2465265.

Gudz OV, Kamilova IK, Miklin OP (2016). "HPV infection of the cervix uteri: Prospects for combination treatment". Rossiiskii Vestnik Akushera-ginekologa. 16 (2): 99. doi:10.17116/rosakush201616299-103. ISSN 1726-6122.

Sand Petersen C, Weismann K (September 1996). "Isoprenosine improves symptoms in young females with chronic vulvodynia". Acta Dermato-Venereologica. 76 (5): 404. doi:10.2340/0001555576404404. PMID 8891022.

Femiano F, Gombos F, Scully C (August 2001). "Oral proliferative verrucous leukoplakia (PVL); open trial of surgery compared with combined therapy using surgery and methisoprinol in papillomavirus-related PVL". International Journal of Oral and Maxillofacial Surgery. 30 (4): 318–322. doi:10.1054/ijom.2001.0066. PMID 11518355.

Pachuta DM, Togo Y, Hornick RB, Schwartz AR, Tominaga S (April 1974). "Evaluation of isoprinosine in experimental human rhinovirus infection". Antimicrobial Agents and Chemotherapy. 5 (4): 403–408. doi:10.1128/aac.5.4.403. PMC 428983. PMID 15825396.

Beran J, Šalapová E, Špajdel M (November 2016). "Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study". BMC Infectious Diseases. 16 (1): 648. doi:10.1186/s12879-016-1965-5. PMC 5100179. PMID 27821093.

Beran J, Špajdel M, Slíva J (November 2021). "Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course". Viruses. 13 (11): 2246. doi:10.3390/v13112246. PMC 8619495. PMID 34835052.

Beran J, Špajdel M, Katzerová V, Holoušová A, Malyš J, Finger Rousková J, et al. (December 2020). "Inosine Pranobex Significantly Decreased the Case-Fatality Rate among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic". Pathogens. 9 (12): 1055. doi:10.3390/pathogens9121055. PMC 7766462. PMID 33339426.

Jayanthi CR, Swain AK, Ganga RT, Halnor D, Avhad A, Khan MS, et al. (September 2022). "Efficacy and Safety of Inosine Pranobex in COVID-19 Patients: A Multicenter Phase 3 Randomized Double-Blind, Placebo-Controlled Trial". Advanced Therapeutics. 5 (12) 2200159. doi:10.1002/adtp.202200159. PMC 9539257. PMID 36246300.

Indries M (December 2013). "Clinical and histological corelations in chronic viral hepatitis C". BMC Infectious Diseases. 13 (S1): 52. doi:10.1186/1471-2334-13-s1-p52. ISSN 1471-2334. PMC 3882649.

Pardo M, Carreño V (August 1994). "Lack of efficacy of inosine pranobex in the treatment of chronic hepatitis C". Journal of Hepatology. 21 (2): 278. doi:10.1016/s0168-8278(05)80410-6. PMID 7527438.

Бабаченко, И. В. (2024-01-10). Эффективность Инозина Пранобекса в лечении и профилактике инфекционных заболеваний (систематический обзор). Journal Infectology Журнал инфектологии (in Russian). 15 (4): 42–53. doi:10.22625/2072-6732-2023-15-4-42-53. ISSN 2072-6732.

Diaz-Mitoma F, Turgonyi E, Kumar A, Lim W, Larocque L, Hyde BM (January 2003). "Clinical Improvement in Chronic Fatigue Syndrome Is Associated with Enhanced Natural Killer Cell-Mediated Cytotoxicity: The Results of a Pilot Study with Isoprinosine". Journal of Chronic Fatigue Syndrome. 11 (2): 71–95. doi:10.1300/J092v11n02_06. ISSN 1057-3321.

Campling F, Sharpe M (2008-07-03). "Some myths about CFS/ME". Chronic fatigue syndrome (CFS/ME). Oxford University PressOxford. pp. 57–60. doi:10.1093/oso/9780199233168.003.0009. ISBN 978-0-19-923316-8.

Huttenlocher PR, Mattson RH (June 1979). "Isoprinosine in subacute sclerosing panencephalitis". Neurology. 29 (6): 763–771. doi:10.1212/WNL.29.6.763. PMID 88024.

De Simone C, Famularo G, Tzantzoglou S, Moretti S, Jirillo E (January 1991). "Inosine pranobex in the treatment of HIV infection: a review". International Journal of Immunopharmacology. 13 (Suppl 1): 19–27. doi:10.1016/0192-0561(91)90120-v. PMID 1726683.

Campoli-Richards DM, Sorkin EM, Heel RC (November 1986). "Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy". Drugs. 32 (5): 383–424. doi:10.2165/00003495-198632050-00001. PMID 2431857.

eco-vector.com (Global: low place; English: low place)

journals.eco-vector.com

Osidak LV, Obraztsova EV (April 2012). "Efficacy of the Inosine pranobex molecule in therapeutic and pediatric practice". Èpidemiologiâ i Infekcionnye Bolezni. Aktual'nye voprosy. [Epidemiology and Infectious Diseases. Current Items] (in Russian). 15 (4): 26-32 https://journals.eco-vector.com/2226-6976/article/view/275885.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Gordon P, Brown ER (September 1972). "The antiviral activity of isoprinosine". Canadian Journal of Microbiology. 18 (9): 1463–1470. doi:10.1139/m72-224. PMID 4341918.

Alseth I, Dalhus B, Bjørås M (June 2014). "Inosine in DNA and RNA". Current Opinion in Genetics & Development. 26: 116–123. doi:10.1016/j.gde.2014.07.008. PMID 25173738.

Hashimoto K, Hosoya M (January 2021). "Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis". Molecules. 26 (2): 427. doi:10.3390/molecules26020427. PMC 7830519. PMID 33467470.

Huttenlocher PR, Mattson RH (June 1979). "Isoprinosine in subacute sclerosing panencephalitis". Neurology. 29 (6): 763–771. doi:10.1212/WNL.29.6.763. PMID 88024.

Glasky AJ, Gordon JF (1987-01-01). "Isoprinosine (inosine pranobex BAN, INPX) in the treatment of AIDS and other acquired immunodeficiencies of clinical importance". Cancer Detection and Prevention. Supplement. 1: 597–609. PMID 2446760.

ncbi.nlm.nih.gov

web.archive.org (Global: 1^st place; English: 1^st place)

"Inosine Pranobex". American Cancer Society. Archived from the original on 23 August 2010. Retrieved 31 July 2013.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Krejsek J, Andrýs C, Krčmová I (2016). Imunologie člověka [Human immunology] (in Czech). Czechia: Garamon sro, Hradec Králové. OCLC 982100822.

Gołębiowska-Wawrzyniak M, Markiewicz K, Kozar A, Derentowicz P, Siwińska-Gołębiowska H (2004-06-30). "The Study on Therapeutic Efficacy of Inosine Pranobex in Children". Polish Journal of Food and Nutrition Sciences. 54 (2s): 33–36. ISSN 1230-0322.

Indries M (December 2013). "Clinical and histological corelations in chronic viral hepatitis C". BMC Infectious Diseases. 13 (S1): 52. doi:10.1186/1471-2334-13-s1-p52. ISSN 1471-2334. PMC 3882649.

Inosine pranobex (English Wikipedia)

acs.org (Global: 1,248^th place; English: 1,104^th place)

cancer.org (Global: 3,680^th place; English: 2,918^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugbank.com (Global: low place; English: low place)

go.drugbank.com

eco-vector.com (Global: low place; English: low place)

journals.eco-vector.com

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

hzg.de (Global: low place; English: low place)

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

niidi.ru (Global: low place; English: low place)

journal.niidi.ru

pan.olsztyn.pl (Global: low place; English: low place)

journal.pan.olsztyn.pl

prolekare.cz (Global: low place; English: low place)

tribune.cz (Global: low place; English: low place)

web.archive.org (Global: 1^st place; English: 1^st place)

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Inosine pranobex (English Wikipedia)

acs.org (Global: 1,248th place; English: 1,104th place)

cancer.org (Global: 3,680th place; English: 2,918th place)

doi.org (Global: 2nd place; English: 2nd place)

drugbank.com (Global: low place; English: low place)

go.drugbank.com

eco-vector.com (Global: low place; English: low place)

journals.eco-vector.com

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

hzg.de (Global: low place; English: low place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

niidi.ru (Global: low place; English: low place)

journal.niidi.ru

pan.olsztyn.pl (Global: low place; English: low place)

journal.pan.olsztyn.pl

prolekare.cz (Global: low place; English: low place)

tribune.cz (Global: low place; English: low place)

web.archive.org (Global: 1st place; English: 1st place)

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

acs.org (Global: 1,248^th place; English: 1,104^th place)

cancer.org (Global: 3,680^th place; English: 2,918^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

harvard.edu (Global: 18^th place; English: 17^th place)

nih.gov (Global: 4^th place; English: 4^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

worldcat.org (Global: 5^th place; English: 5^th place)